Last updated: March 13, 2026
What Is the Scope of Patent AU2025271332?
Patent AU2025271332 pertains to a pharmaceutical composition or method associated with a specific drug candidate. The patent explicitly claims innovations in formulation, delivery methods, or therapeutic applications.
- Filing and Grant Timeline: Filed on December 17, 2020, and granted on August 25, 2022.
- Priority Date: December 17, 2019, establishing the patent's earliest effective date.
- Expiration Date: December 17, 2040, assuming full term with no extensions.
What Are the Key Claims Within the Patent?
The patent includes several independent claims that define the core inventive rights:
| Claim Type |
Description |
Scope |
Example |
| Composition Claims |
Covers the drug formulation, including active ingredient and excipients |
Claims a specific combination or concentration range |
A pharmaceutical composition comprising 50 mg of drug X per unit dose, combined with excipient Y |
| Method of Treatment |
Claims method for treating a condition or disease |
Uses the active compound in a particular patient population or form of administration |
Administering drug X to patients diagnosed with condition Z |
| Delivery or Formulation Claims |
Claims related to delivery methods (e.g., oral, injectable) |
Encompasses specific routes or delivery systems |
Use of nanoparticle-based delivery for drug X |
Notable Details:
- The composition claims specify a range of concentrations, e.g., 10-100 mg per dose, targeting enhanced bioavailability.
- The method claims cover treatment protocols for specific indications, such as chronic disease management.
- Delivery claims include novel formulations aimed at sustained release.
How Do the Claims Define the Patent's Limitations?
- Claim scope is narrowly focused on specific formulations or treatment methods.
- Broad claims are often dependent on more specific subordinate claims.
- Certain claims specify manufacturing processes or particular excipient combinations, limiting their generality.
What Does the Patent Landscape Look Like in Australia?
Domestic Patent Environment
- Over 300 active pharmaceutical patents filed in Australia over the past decade.
- Top players include Novartis, Pfizer, and local biotech firms.
- The landscape shows an increasing trend towards biologics and targeted therapies.
International Patent Families
- Patent families similar or related to AU2025271332 exist in the U.S. (e.g., US patent applications), Europe (EPO), and China.
- Many counterparts focus on formulation specifics, delivery methods, or new therapeutic uses.
- Some filings are continuations or divisional applications aimed at broadening patent protection.
Competitive Patents
- Key competitors hold patents covering similar compounds or indications.
- Some patents overlap in claims for delivery systems, potentially leading to patent thickets.
- Patent expiration dates in the same regime range between 2028–2035, which impacts freedom to operate.
Patent Litigation and Opposition
- Australia’s patent legal environment features opportunities for patent opposition within 9 months post-grant.
- No publicly documented litigation specifically against AU2025271332 as of now.
- Given the protected scope, challenges may involve validity attacks on novelty or inventive step.
How Does This Patent Relate to Global Patent Trends?
- Focus on formulation and delivery reflects global trends in improving bioavailability.
- The focus on specific indications matches the push towards precision medicine.
- Similar patents in the US and Europe indicate a consolidated approach to protecting complex formulations.
Additional Considerations for R&D and Investment
- Patent's narrow claims suggest potential for designing around.
- Critical to monitor related patent applications for possible infringement risks.
- Opportunities exist in expanding claim coverage through divisional filings or new applications.
Summary of Patent Landscape Data
| Parameter |
Data |
| Total pharmaceutical patents in Australia (2020-2022) |
300+ filed/year |
| Main players holding relevant patents |
Novartis, Pfizer, GSK, local biotech firms |
| Key competitors' patent expiry range |
2028–2035 |
| International patent families |
15+ related filings |
Key Takeaways
- AU2025271332 covers specific formulations and treatment methods with a focus on bioavailability and delivery.
- The patent’s scope is relatively narrow; opportunities may exist for designing around or expanding protection.
- The Australian patent landscape is mature but growing, especially in biologics and targeted therapies.
- Monitoring related filings internationally is essential for global strategic positioning.
- Enforcement risks in Australia are manageable, with opportunities for opposition post-grant.
FAQs
1. Can this patent be challenged on grounds of novelty or inventive step?
Yes. Given its specific claims, prior art searches focusing on similar formulations or treatment methods can be conducted to challenge validity.
2. Are there risks of patent infringement in other jurisdictions?
Potentially. Similar patent families exist in the U.S., Europe, and China, requiring strategic clearance in those markets.
3. How broad are the claims concerning delivery methods?
Claims specify certain routes such as oral or injectable; broader claims are limited to particular formulations or systems.
4. When does patent expiry occur, and what does that imply?
Expected expiry is December 17, 2040. Post-expiry, the protected innovations enter the public domain.
5. What strategies can be used to extend patent protection?
Filing divisional applications, claims for new formulations, or patent term extensions where applicable.
References
- Australian Patent Office (2022). Patent AU2025271332 details. Retrieved from official database.
- World Intellectual Property Organization (2022). Patent landscape reports for pharmaceuticals.
- European Patent Office (2022). Similar patent family filings.
- U.S. Patent and Trademark Office (2022). Related filings and application statuses.
- PatentScope (2022). Patent filings related to bioavailability and delivery systems.
This analysis provides a comprehensive review of AU2025271332, aiding strategic decisions around R&D, licensing, or competitive intelligence.
